エリ・リリーの肥満薬の謎
原題: The mysterious case of Eli Lilly’s obesity drug
分析結果
- カテゴリ
- 医療
- 重要度
- 57
- トレンドスコア
- 18
- 要約
- エリ・リリー社の肥満治療薬に関する事例は、効果や副作用についての不明点が多く、注目を集めています。この薬は、肥満治療において新たな選択肢を提供する可能性がある一方で、長期的な影響や安全性についての懸念も存在します。医療界や患者の間での議論が続いており、今後の研究結果が期待されています。
- キーワード
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD." Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD." Who got exclusive access to Eli Lilly’s highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company’s obesity candidate, retatrutide, through the FDA’s “compassionate use” program. Read the rest…